Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Extension Study of Ibrutinib (PCI-32765) in B-cell Malignancies
jRCT2011200019Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2021
- Modality
- Small Molecules
01
Overview
Phase 3, open-label trial of ibrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), mantle cell lymphoma (MCL) and follicular lymphoma (FL) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Number of participants affected by an adverse event. Started May 2021; status: active, not recruiting.
02
Drugs
ibrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)mantle cell lymphoma (MCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on jRCT2011200019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011200019.